Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1719

Accelerated Wound Healing in Megakaryocyte/Platelet-Specific Fli1 Knockout Mice Due to the up-Regulated Expression of Interferon-γ

9:00AM-11:00AM: Abstract Number: 1709

Classical Monocytes in the Pathogenesis of Early Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1713

Defining Genetic Risk for Scleroderma Renal Crisis in RNA-Polymerase III Antibody Positive Patients

9:00AM-11:00AM: Abstract Number: 1706

Dipeptidyl-Peptidase-4 (DPP4) Promotes Fibroblast Activation and Is a Potential Molecular Target for Treatment of Fibrosis

9:00AM-11:00AM: Abstract Number: 1710

Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells Enhances the Transition of Endothelial to Mesenchymal Cells (Endo-MT) Induced By TGFβ through Down-Regulating PI3/Akt Signaling Pathway By Targeting PIK3R2

9:00AM-11:00AM: Abstract Number: 1707

Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 1727

Genome-Wide DNA Methylation Analysis in Systemic Sclerosis Reveals Hypomethylation of Interferon-Associated Genes in CD4+ and CD8+ T Cells

9:00AM-11:00AM: Abstract Number: 1726

Human Skin in Organ Culture As an Ex Vivo Model for Assessing the Fibrotic Effects of Bleomycin

9:00AM-11:00AM: Abstract Number: 1722

Identification of a Sub-Population of Autoantibodies Targeting BICD2 Cross-Reacting with CENP-a Derived Peptides in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1730

IL-6 Mediates Activation of Macrophages in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1729

Increased Serum Levels of Micro-RNA 30d and Micro-RNA 423-5p in 2 Independent Cohorts of Patients with Morphea

9:00AM-11:00AM: Abstract Number: 1705

Inhibition of EZH2 Stops Fibrosis and Improves Angiogenesis in Scleroderma

9:00AM-11:00AM: Abstract Number: 1714

Inhibition of Hedgehog Acyltransferase Alleviates the Profibrotic Effects of Transforming Growth Factor β in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1725

Insulin-like Growth Factor Binding Protein-4 Exerts Anti-Fibrotic Effects and Its Levels Are Reduced in SSc-Associated Lung Fibrosis

9:00AM-11:00AM: Abstract Number: 1728

Interferon Gamma (IFN-γ) Subpopulations in Skin Homing T Cells of Localized Scleroderma

9:00AM-11:00AM: Abstract Number: 1721

Long Noncoding RNA H19X Is a Key Regulator of Apoptosis and Proliferation of Fibroblasts in Systemic Sclerosis and Other TGFβ-Driven Fibrotic Diseases

9:00AM-11:00AM: Abstract Number: 1724

Metabolic Regulation of Fibrosis in Systemic Sclerosis: The CD38-NAD+ Link

9:00AM-11:00AM: Abstract Number: 1712

Microbial and Metabolic MULTI-Omic Correlations in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 1715

Mitochondrial DNA Mutations and Respiratory Chain Dysfunction in Lung Fibrosis of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1708

Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1723

Nuclear Magnetic Resonance Based Metabolomics Study Identifies Highly Discriminatory Metabolites in 87 Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 1711

SIRT1 May Protect Against Systemic Sclerosis-Related Pulmonary Fibrosis By Decreasing Pro-Inflammatory and Pro-Fibrotic Processes

9:00AM-11:00AM: Abstract Number: 1717

Skin Commensal Bacteria Might Affect Wound Repair in SSc By Preventing Fibroblast Activation and By Provoking Chronic Inflammatory Reaction

9:00AM-11:00AM: Abstract Number: 1720

TGF-ß-Induced Tissue Fibrosis in TBRIcaCol1Cre Transgenic Mice Is Abrogated By the Second Generation Tyrosine Kinase Inhibitor SKI-606 (Bosutinib)

9:00AM-11:00AM: Abstract Number: 1716

TGFβ-Dependent Upregulation of XIAP Fosters Fibroblast Activation and Tissue Fibrosis By Promoting Canonical Wnt Signaling

9:00AM-11:00AM: Abstract Number: 1718

The Role and Function of Monocyte-Derived Fibroblast-like Cells in Multi-Organ Fibrosis in Systemic Sclerosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].